BTK Inhibitors in CLL: Second Generation Drugs and Beyond onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Researchers found that, despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.
Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy